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A COMPARATIVE STUDY OF EQUIPOTENT DOSES OF DEXMEDETOMIDINE AND 
CLONIDINE AS ADDITIVE TO HYPERBARIC BUPIVACAINE IN SPINAL ANAESTHESIA 
ABSTRACT 
Background: The purpose of this study was to compare the onset and duration of sensory and motor 
block, as well as the hemodynamic changes and level of sedation, following intrathecalbupivacaine 
supplemented with either dexmedetomidine or clonidine. 
Methods: In a prospective, double-blind study, 94 patients undergoing infra- umblical surgeries under 
spinal anesthesia were randomly allocated to one of three groups. Group B received 12.5 mg of 
hyperbaric bupivacaine, group D received 12.5 mg of bupivacaine supplemented with 5 µg of 
dexmedetomidine and group C received 12.5 mg of bupivacaine supplemented with 50 µg of clonidine. 
The onset times to reach peak sensory and motor levels, and the sensory and motor regression times, 
were recorded. Hemodynamic changes and the level of sedation were also recorded. 
Results: Patients in groups D and C had a significantly shorter onset time of motor block and 
significantly longer sensory and motor regression times than patients in group B. The mean time of 
sensory regression to the S1 segment was 337 min in group D, 265 min in group C and 179 min in group 
B (B vs. D and B vs. C, P < 0.001). The regression of motor block to Bromage 0 was 262.41 min in 
group D, 205.9 min in group C and 148.55 min in group B (B vs. D and B vs. C, P < 0.0001). The onset 
and regression times were significantly different between groups D and C. Both Clonidine and 
dexmedetomidine lowered the pulse rate, systolic BP, diastolic BP. But clonidine’s lowering of SBP was 
significant and sustained for a prolonged period. Similarly clonidine produced a much deeper and 
prolonged plane of sedation in comparison to dexmedetomidine. 
Conclusions: In comparision to clonidine (50 µg), Dexmedetomidine (5 µg) when added to intrathecal 
bupivacaine, produces a prolonged duration of the motor and sensory block with better hemodynamic 
stability. 
Key words: α2 adrenergic agonist, Clonidine, Dexmedetomidine, hyperbaric bupivacaine, Spinal 
anaesthesia. 
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AIM OF THE STUDY 
 
To compare the effect of addition of equipotent doses of Clonidine 
(50 µg) and Dexmedetomedine (5 µg) in 0.5 ml normal saline, respectively 
added to 2.5 ml of 0.5%  Hyperbaric Bupivacaine (making it a total of  3 
ml) in spinal anaesthesia for sub umbilical surgeries 
 
To evaluate: 
• Time to onset of sensory and motor block 
• Duration of sensory and motor block 
• Duration of effective post operative analgesia 
• Side effects 
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INTRODUCTION 
Spinal anaesthesia is commonly used for abdominal, perineal, 
gynaecological and lower limb operations. It offers excellent anaesthesia 
and fewer side effects than general anaesthesia. It is easy to perform and 
provides faster onset and effective sensory and motor block. Bupivacaine 
produces long lasting spinal anaesthesia without transient neurological 
symptoms. Recently there has been an interest in using additives to intra 
thecal local anasesthetics to decrease the dose of local anaesthetics and also 
to provide effective post operative analgesia. 
Dexmedetomidine an α2-adrenergic agonist that has been used for 
pre-medication and as an adjunct to general anesthesia as well as a sole 
anesthetic agent and also as a sedation agent in the intensive care unit
31,26
. 
Dexmedetomidine has been used intrathecally in animals and was found to 
be a very potent antinociceptive agent32-34. It has been used in the epidural 
space in humans without any reports of neurological deficits
35
.
 
Dexmedetomidine used intravenously, significantly prolonged the sensory 
and motor block of spinal Prilocaine36. Dexmedetomidine (3 µg) with 
Bupivacaine, as spinal anesthetic, in humans, produced shorter onset and 
prolonged the duration of motor and sensory block with hemodynamic 
stability and lack of sedation37.  Clonidine is an α2-adrenergic agonist that is 
often administered intrathecally in humans. It has been given in doses upto 
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450 µg in dosing studies, but was found that the duration of both sensory 
and motor block plateaued at 150 µg of Clonidine
32-34,39
. Animal studies
32,34
,
 
had shown that a 1:10 dose ratio between intrathecal Dexmedetomidine and 
Clonidine, produced a similar effect. The potency of an epidurally 
administered α2-adrenergic agonist was well correlated with their binding 
affinity to the spinal α2-adrenergic receptor. Therefore, we used larger 
equipotent doses of  Dexmedetomidine (5 µg)  and Clonidine (50 µg)  in the 
spinal anesthesia combined with Bubivacaine than previous study to 
investigate the effect of adding this doses on the onset and regression of 
sensory and motor block together with hemodynamic and sedation changes 
versus intrathecal Bupivacaine alone.  
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SPINAL ANAESTHESIA AND ADJUVANTS 
Spinal (subarachnoid/intrathecal) anaesthesia is a form of central 
neuraxial block in which a temporary interruption of nerve transmission is 
achieved following injection of local anaesthetic/ adjuvant solutions into 
subarachnoid space.  
Subarachnoid block is one of the most commonly performed methods 
of regional anaesthesia. 
Anatomy 
The vertebral canal extends from foramen magnum to the sacral 
hiatus. Its boundaries are the dorsal spine, pedicles and laminae of 
successive vertebrae (7 cervical, 12 thoracic, 5 lumbar and 5 sacral). The 
vertebrae are held together by overlapping ligaments namely, anterior and 
posterior longitudinal ligaments, ligamentum flavum, interspinous ligament, 
supraspinous ligament and the intervertebral discs. 
The spinal cord is a direct continuation of medulla oblongata, begins 
at the upper border of atlas and terminates distally in the conusmedullaris. 
The distal termination, because of the differential growth rates between the 
bony vertebral canal and spinal cord varies from L3 in the infant to lower 
border of L1 in the adult. 
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 Surrounding the spinal cord in the bony vertebral column are 3 
membranes (from within to periphery): the pia mater, arachnoid mater and 
the dura mater. The pia mater is a highly vascular membrane that closely 
invests the spinal cord. The arachnoid mater is a delicate non vascular 
membrane closely attached to outermost dura mater. 
STRUCTURES TO BE PIERCED FOR SUBARACHNOID BLOCK 
Between the 2 innermost membranes is the subarachnoid space. In 
this space, 
cerebrospinal fluid 
(CSF), spinal nerves, 
blood vessels that 
supply the spinal cord 
and dentate ligaments 
are present. Although the spinal cord ends at lower border of L1 in adults, 
the subarachnoid space continues upto S2. The outermost membrane in the 
spinal cord is the longitudinally organised fibroelastic membrane, the dura 
mater. This layer is the direct extension of cranial dura mater and extends as 
spinal dura mater from foramen magnum to S2, where filum terminale 
blends with periosteum of subdural space which contains small amounts of 
serous fluid to allow dura and arachnoid to move over each other.  
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Surrounding the dura mater is the epidural space which extends from 
foramen magnum to sacral hiatus. Posterior to the epidural space is 
ligamentum flavum. Immediately posterior to the ligamentum flavum is 
interspinous ligament. Extending from external occipital protruberance to 
the coccyx, posterior to this structure is the supraspinous ligament. 
Lumbar puncture is 
routinely performed below L2 
vertebrae down to the L5-S1 
interspace to avoid damage to the 
spinal cord which ends at lower 
border of L1 vertebra in adults. 
PHYSIOLOGY OF 
SUBARACHNOID BLOCK 
Cerebrospinal Fluid 
The cerebrospinal fluid is 
an ultrafiltrate of blood plasma 
which is in hydrostatic and osmotic equilibrium. It is clear, colourless fluid 
found in spinal and cranial subarachnoid space and in ventricles of brain. 
The average volume in adults ranges from 120 to 150 ml of which 35 ml in 
the ventricles, 25 ml is in the cerebral subarachnoid space and 75 ml is in 
the spinal subarachnoid space. It is secreted by choroid plexus at a rate of 
0.3 - 0.4 ml/minute. 
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Physical Characteristics of Cerebrospinal Fluid 
• pH      7.4 
• Specific gravity   1.007 
• Density     1.0003 
• Baricity     1.000 
• Pressure     8-12 mmHg / 70- 80 cm H20 
• Cells      3- 5 /cu.mm 
• Proteins     20 mg/dl 
• Glucose     45 -80 mg/dl 
The cerebrospinal fluid plays an important role in spinal anaesthesia 
as a media for dispersion of the local anaesthetic drug to the spinal nerve. 
An important factor determining the spread of drugs in subarachnoid space 
is specific gravity of the injected solution compared with that of CSF. 
MECHANISM OF SPINAL ANAESTHESIA 
Injection of local anaesthetics into the spinal CSF allows access to 
sites of action both within the spinal cord and the peripheral nerve roots. 
The nerve roots leaving the spinal canal are not covered by epineurium and 
are readily exposed to the local anaesthetic within CSF. Therefore afferent 
impulses leaving via ventral nerve roots are blocked during spinal 
anaesthesia. Spinal local anaesthetics block sodium channels and electrical 
conduction in spinal nerve roots. Local anaesthetics can exert sodium 
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channel block within the dorsal and ventral horns inhibiting the generation 
and propagation of electrical activity. 
The order in which nerve fibres are blocked in spinal anaesthesia is 
preganglionic sympathetic B fibres followed by temperature fibres (cold 
before warmth), fibres carrying pin prick sensation, touch, deep pressure 
and finally proprioception. Recovery is in the reverse order. The major 
factors determining the level of blockade after subarachnoid block are the 
baricity of the local anaesthetic solution, the position of the patient before 
and after injection and dose of the anaesthetic injected. 
Fate of Local Anaesthetics in Subarachnoid Space 
Following injection of local anesthetic solution into subarachnoid 
space, its concentration falls rapidly. The initial steep fall is due to mixing 
with CSF and subsequent absorption into nerve roots and spinal cord. 
Depending on the type of drug used, it is metabolized in plasma by 
pseudocholinesterase or in the liver. The addition of a vasopressor to the 
local anesthetic will retard the absorption of the drug and thus increase the 
duration of anaesthesia. 
Indications for subarachnoid block 
Spinal anaesthesia can be administered whenever a surgical procedure 
can be done with a sensory level of anaesthesia that does not produce 
adverse patient outcome which includes, 
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• Lower abdominal surgeries 
• Lower limb surgeries 
• Urological procedures 
• Obstetric & gynaecological procedures 
• Perineal and rectal surgeries 
Contra indications for subarachnoid block 
An absolute contraindication for subarachnoid block is patient refusal. 
Other contraindications are: 
• Local sepsis 
• Uncorrected coagulopathy 
• Uncontrolled blood loss / shock 
• Fixed cardiac output states 
• Documented allergy to local anaesthetics 
• Raised intracranial pressure 
• Neurological disease 
• Major spine deformities /previous surgery on the spine 
• Severe cardiac disease. 
Spinal Anaesthesia Technique 
The first step in successful application of spinal anaesthesia is proper 
patient selection. This is accomplished by pre-anaesthetic evaluation of the 
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patient through history, physical examination, laboratory data and 
communication with patient and surgical staff about details of the 
procedure. Reliable intravenous access through a large bore intravenous 
canula (18G /16G) is mandatory. Preloading limits the hypotension that may 
result from sympathetic block. The recommended standards for airway 
management and emergency drugs are kept in readiness.  
PROCEDURE 
Preparation 
Preparation of equipment and drugs is essential for performing a 
subarachnoid block. The choice of drug is 
based on duration of block desired, the 
surgical procedure and patient variables. 
Spinal needles of various diameters with 
various types of points are available. Spinal 
needles fall into two main categories: those 
that cut the dura and those that are designed 
to separate the dural fibres former includes 
the Quincke-Babcock needle and the latter include the Greene, Whitacre and 
Sprotte needles. In order to keep the incidence of post dural puncture 
headache to a minimum, small bore needles with a rounded non-cutting 
bevel are preferred. 
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POSITION 
The choice of position of the patient for performing the subarachnoid 
block depends on a number of factors - the proposed surgery being the most 
important. 
Lateral Decubitus Position 
 In the lateral decubitus position, the 
patient is placed with back parallel to the 
edge of the operating table nearest the 
anaesthesiologist with thigh flexed upon the 
abdomen and neck flexed. 
 
Sitting Position 
The sitting position is chosen 
when low lumbar and sacral levels of 
anaesthesia are adequate for the surgical 
procedure or when obesity or scoliosis 
makes identification of midline anatomy 
difficult in lateral decubitus position or when orthopaedic problems of hip 
and knee exist. 
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Projection and Puncture 
The spinal puncture can be performed either by a midline or a 
paramedian approach, usually at the L2-L3, L3-L4, L4-L5 interspaces. The 
procedure is carried out under strict aseptic conditions. 
The patients back is prepared with an antiseptic solution and sterile 
drapes are applied. A line from the highest point of iliac crest passes 
through either spinous process of L4 or the L4-L5 interspace. The midline 
approach with the patient in sitting position /right lateral decubitus position 
is used in our study. Depending on the interspace and approach selected, 
subcutaneous skin wheal is raised over the intended puncture site with local 
anaesthetic solution. The needle is inserted in the middle of the interspace 
with bevel parallel to the longitudinal dural fibres. After traversing the skin 
and subcutaneous tissue, the needle is advanced in a slightly cephalad 
direction with the long axis of the vertebral column. The stylet is removed 
and appearance of cerebrospinal fluid at the hub of the needle confirms 
correct position of the needle tip. Stylet is reinserted to prevent excess 
leakage of CSF. The hub of the needle is firmly held between the thumb and 
index finger of the anaesthesiologist’s non dominant hand and back of hand 
held against patients back to steady the needle, while syringe containing 
anaesthetic solution is firmly attached to the needle. 
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After confirming free flow of spinal fluid by aspiration, the 
anaesthetic solution is injected. The patient is placed in supine position. 
Cardiovascular and respiratory functions are monitored. Analgesia is 
checked by loss of sensation to pin prick. Motor block assessed by modified 
Bromage score. 
In the recent past various additives have been added to local 
anaesthetic solution - vasopressors, opioids, alpha 2 adrenergic agonists and 
acetyl choline esterase inhibitors. These produce prolongation of analgesia 
after subarachnoid block and reduce the dose requirement of local 
anaesthetics. 
COMPLICATIONS OF SUB ARACHNOID BLOCK 
Immediate 
1. Hypotension 
2. Bradycardia 
3. Toxicity due to intravascular injection 
4. Allergy to local anaesthetic 
5. Hypoventilation (brainstem hypoxia) 
Late 
1. Post dural puncture headache 
2. Retention of urine 
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3. Backache 
4. Meningitis 
5. Transient lesions of cauda equina 
6. Sixth nerve palsy 
7. Anterior spinal artery syndrome 
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PHARMACOLOGY OF BUPIVACAINE 
Bupivacaine is an amide local anaesthetic synthesised by 
A.F.Ekenstam in 1957 and brought into clinical use in 1963. 
It is produced for clinical use in a racemic mixture containing equal 
proportions of the ‘S’ and ‘R’ enantiomers. It is supplied for clinical use as 
hydrochloride salt. 
Chemical structure 
 
Description: +1-butyl-N-(2,6-dimethylphenyl)-2-piperidine Decarboxamide 
Hydrochloride monohydrate. 
Physio-chemical profile: 
Molecular weight (base)  - 288 
pKa     - 8.1 
Solubility In: 
Alcohol    - 1 in 8 
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Water     - 1 in 25 
Octanol/water partition coefficient- high 
Lipid solubility   - 28 
Plasma protein binding  - 95% 
Mechanism of action 
Bupivacaine exerts its effect by inhibition of sodium channels. It acts 
to block conduction in nerves by decreasing or preventing the large transient 
increases in permeability of cell membrane to sodium ions that follows 
depolarisation of the membrane. Bupivacaine also reduces the permeability 
of the resting nerve membrane to potassium as well as sodium ions. 
Pharmacodynamics 
Bupivacaine by virtue of its pharmacological effects has a stabilizing 
action on all excitable membranes. The clinical profile of nerve blockade 
produced by bupivacaine differs from that of lignocaine. 
It is 4 times more potent than lignocaine, but the onset of action is 
slower. The duration of action is considerably longer. The sensory block 
produced by bupivacaine tends to be more marked than the motor block. 
Pharmacokinetics 
Bupivacaine is rapidly absorbed from the site of injection. The rate of 
rise in plasma bupivacaine concentration and the peak plasma 
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concentrations depend on the route of administration. There is also some 
inter individual variation and peak systemic concentrations may occur 5 and 
30 mins after administration. The addition of vasoconstrictor delays 
absorption and results in lower plasma concentrations of bupivacaine. 
Pharmacokinetic profile 
6
 
Volume of distribution at steady state (Vdss) 72 litres 
Clearance       0.47 l/min 
t l/2 α        2.7 min 
t l/2β        28 min 
t l/2γ        3.5 hrs 
Metabolism 
Possible pathways for metabolism of bupivacaine include aromatic 
hydroxylation, N dealkylation, amide hydrolysis and conjugation. Only the 
N-dealkylated metabolite, N-desmethyl bupivacaine has been measured in 
blood and urine after epidural and spinal administration. The degradation of 
bupivacaine takes place in the liver. Renal disease is unlikely to alter the 
kinetics of bupivacaine to any great extent. Less than 10% of the drug is 
excerted unchanged in urine
6
. 
Clinical applications 
- Infiltration anaesthesia 
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- Peripheral nerve blocks 
- Central neuraxial blocks (intrathecal, epidural, caudal) 
 
Contraindications 
- Paracervical block (in obstetrics) 
- Known hypersensitivity to amide local anaesthetics 
- Intra venous regional anaesthesia (IVRA) 
Preparations available 
• 0.25%, 0.5% solutions in l0 ml and 20 m1 vials 
• 5 mg/ml (0.5%) bupivacaine and 80 mg dextrose in 4 m1 
ampoules for intrathecal injection (Baricity 1.0207) 
Recommended safe dose 
Concentration used Max permitted dose 
0.125% - 0.5%  3 mg/kg body weight 
0.75%  (not to be used in obstetric 
epidurals) 
Max over 4 hrs - 150 mg  
Max during 24 hrs - 4000 mg 
0.5% plain/hyperbaric (intrathecal use) 20 mg 
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Adverse reactions 
Adverse reactions are associated with excess plasma levels of the 
drug which may be due to overdosage, unintentional intravascular injection 
or slow metabolic degradation. 
CNS Reactions 
Excitation characterized by restlessness, anxiety, dizziness, tinnitus, 
blurred vision or tremors possibly proceeding to convulsions, followed by 
drowsiness, unconsciousness and cardiac arrest. 
CVS 
Part of the blockade that occurs from high plasma concentrations of 
bupivacaine occurs because of blockade of cardiac sodium channels. 
Accidental intravenous injection of bupivacaine causes cardiac 
dysarrythmias, atrioventricular block, refractory ventricular tachycardia and 
ventricular fibrillation. Pregnancy increases the sensitivity of cardiotoxic 
effects of bupivacaine. 
Bupivacaine binds and inhibits cardiac voltage gated calcium and 
potassium channels at concentrations greater than those at which binding to 
sodium channel is maximal. 
Unlike other local anaesthetics, bupivacaine dissociates from blocked 
sodium channels at a much slower rate, resulting in prolongation of 
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maximal rate of depolarization (Vmax) and creating the potential for re-
entrant type of ventricular arrhythmias. 
Allergic reactions 
Manifests as urticaria, pruritis, angioneurotic edema etc. Cross 
sensitivity among members of amide local anaesthetics has been reported. 
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PHARMACOLOGY OF CLONIDINE HYDROCHLORIDE 
Clonidine a imidazoline derivative is a selective partial agonist for 
alpha 2 adrenergic receptors. It is known to increase sensory and motor 
block of local anaesthetics. 
Its action is mediated spinally through activation of post synaptic 
alpha 2 receptors in the substantia gelatinosa of spinal cord. 
Physical chemistry 
C9H9N3 Cl2HCl 
 
2,6 DichloroN-2 imidazolidinyiedlenebenzenarnine : hydrochloride 
1. Molecular weight (free base)  266.6 (230.1) 
2. pKa      8.05 
3. Solubility in alcohol   1 in 25 
4. Solubility in water    1 in 13 
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5. Octanol/water partition co-efficient 3.02 
Clonidine hydrochloride is a white crystalline, odourless powder with 
a bitter taste.  
Pharmacology 
Clonidine is a partial agonist at alpha 2 adrenoceptors both within the 
central nervous system and in the periphery. It is more specific for alpha 2 
than for alpha 1 with a ratio of affinities at these sites at approximately 
300:1. Within the CNS alpha 2 adrenoceptors are located both 
presynaptically on terminals of neurons which release a variety of 
transmitters (nor epinephrine, epinephrine, serotonin and acetylcholine) and 
post synaptically on noradrenergic neurons. 
Mechanism of Clonidine as an adjuvant in central neuraxial blockade 
Intrathecal clonidine increases the duration of both sensory and motor 
block. The mechanism of clonidine induced potentiation of sensory block in 
spinal anaesthesia is mediated by presynaptic (inhibition of transmitter 
release) and post synaptic (enhancing hyperpolarisation) 
The reason for potentiation of motor block seems to be 
hyperpolarisation of ventral horn neurons of spinal cord. This is dose 
related. 
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Clonidine blocks conduction of C and A delta fibres and increases 
potassium conductance in neurons and also intensifies conduction block of 
local anaesthetics. Clonidine may cause local vasoconstriction
12
. 
EFFECTS ON ORGAN SYSTEMS 
Cardiovascular System 
Oral or intra venous administration of Clonidine causes a dose 
dependent fall in blood pressure and heart rate in both supine and erect 
position, with the orthostatic response being most prominent 
Clonidine affects blood pressure in a complex fashion. In nucleus 
tractus solitarius and locus ceruleus of brain stem activation of post synaptic 
alpha 2 adrenoreceptors reduces sympathetic drive. In addition it activates 
noradrenergic binding sites in lateral reticular nucleus thereby producing 
hypotension and antiarrythmogenic action. The magnitude of hypotensive 
effect is greater in hypertensive than in normotensive subjects
12
. 
The brainstem and peripheral effects of alpha 2 adrenoreceptor 
stimulation are counter balanced by direct peripheral vasoconstriction from 
circulating concentrations of Clonidine. As a result the dose response for 
Clonidine by neuraxial or systemic administration is U shaped, with 
peripheral vasoconstriction from circulating drug concentrations at high 
doses opposing central sympatholysis. 
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Neuraxial administration 
of Clonidine directly inhibits 
sympathetic preganglionic 
neurons in spinal cord. Degree of 
hypotension is related to spinal 
level of injection. 
The pressor effect of high 
dose of Clonidine is due to peripheral vasoconstriction mediated by 
stimulation of post synaptic alpha 1 and/or alpha 2 adrenoreceptors on 
vascular smooth muscle
21
.  
Respiratory System 
The respiratory depressant effect of Clonidine is not remarkable 
unless massive doses are given. The effect of clonidine is less potent than 
that of opiate narcotics
23
. 
Central Nervous System
20
 
Sedation is one of the most consistent effects mediated by central 
alpha 2 receptors. The locus ceruleus was shown to be the principal region 
responsible for sedative effect. Another characteristic effect of alpha 2 
agonists is anxiolysis which is comparable to the response produced by 
benzodiazepine compounds. 
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Clonidine has a potent analgesic action that cannot be reversed by 
naloxone, an opioid antagonist, indicating that clonidine and opioid mediate 
analgesia through independent receptor mechanism. Clonidine may 
potentiate the effects of bupivacaine by reducing spinal cord blood flow and 
prolonging the effective availability of bupivacaine. 
There is a 50% decrease in MAC of inhalational anesthetics and 
decreased anaesthetic requirements of opioids. At doses of 75 µg, it 
prevents shivering. Clonidine is also effective in suppressing signs and 
symptoms of withdrawal from opioids, benzodiazepines and ethanol. 
Endocrine 
Endocrine and metabolic effects mediated by alpha 2 adrenoreceptor 
stimulation are  
1. Increased TSH and GH secretion  
2. Decreased ACTH and ADH secretion  
3. Inhibition of glucose stimulated insulin release, but this does not 
result in severe hyperglycemia in a clinical setting. 
GIT 
Stimulation by Clonidine of peripheral presynaptic alpha2 
adrenoreceptors on post ganglionic noradrenergic or cholinergic neurons 
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contributes to reduced salivary flow, intestinal motor activity and gastric 
acid secretion. 
Pharmacokinetics 
• Oral absorption    100% 
• Pre systemic metabolism  0-25% 
• Elimination half life   20-25 h 
• Volume of distribution   2 l/kg 
• Plasma protein binding   20-40% 
Clonidine is approximately 60% excreted unchanged in urine. The 
remaining 40% elimination is by oxidative metabolism predominantly in the 
liver. There is no evidence that any metabolites possess significant 
biological activity. Clearance of Clonidine is linearly related to dose over 
75-300 µg. Total plasma clearance is 3 ml/kg/min, while renal clearance 
accounts for 1.8 ml/kg. Clearance may be reduced in the presence of 
abnormal renal functions. Although Clonidine may cross the placenta it does 
not appear to reach concentrations sufficient to affect the fetus. 
Metabolism 
Clonidine is approximately cleared by metabolism predominantly in 
the liver to five inactive metabolites the predominant pathways are: 
hydroxylation of the phenyl ring and opening up of the imidazoline ring 
following an initial reductive step with subsequent oxidative cleavage. The 
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hydroxylated metabolites are subjected to secondary conjugation with 
sulphate or glucoronide prior to urinary excretion. 
DOSAGE OF CLONIDINE IN VARIOUS ROUTES 
S. No. Route Bolus Cont. infusion 
1 Oral 4- 5 µg/kg  
2 IM 2 µg/kg  
3 IV 4- 5 µg/kg  
4 Epidural 75- 450 µg 12.5-70 µg/h 
5 Intrathecal 30-225µg 8 -400 µg/day 
USAGE 
1.  Antihypertensive agent 
2.  Anaesthesia - prolongation of action of local anaesthetic after 
neuraxial administration, pre- medication and post anaesthetic 
shivering 
3.  Opiate withdrawal syndrome 
4.  Glaucoma (Apraclonidine and Brimonidine) 
5.  Migraine prophylaxis 
6.  Provocative tests of growth hormone secretion, in the investigation of 
short stature 
7.  Diagnosis of phaeochromocytoma 
8.  Psychiatric disorders 
9.  Menopausal symptoms 
10.  Chronic diarrhea 
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Contraindications 
Disorders of cardiac impulse generation and conduction like Sino 
atrial disease (Sick Sinus Syndrome), Atrioventricular node disease and 
patients with cardiac pacemakers. 
Adverse Reactions 
Common symptomatic effects are sedation (35-100%), dry mouth (25-90%), 
bradycardia, constipation and contact dermatitis (transdermal clonidine). 
Less common effects include postural hypotension, dizziness, fluid retention 
(weight gain, oedema), sleep disturbances (insomnia, sleep reversal, 
nightmares, hallucinations, reduction of REM sleep), impotence, parotid 
swelling and depression. Uncommon effects are rash, pruritis, angioedema, 
hepatitis, gynecomastia, raynauds phenomenon, thinning of hair, urinary 
retention and agitation. 
Withdrawal syndrome which is characterised by a rapid rise in blood 
pressure, with marked blood pressure lability, symptoms such as headache, 
flushing, sweating, insomnia, agitations, emotional lability, tremor, nausea 
and vomiting presents 18-72 h after the last dose of clonidine. The 
syndrome can be prevented by gradual withdrawal of clonidine over days to 
weeks and, if present controlled by reintroducing clonidine treatment or by 
inhibiting peripheral sympathetic nervous activity, with alpha and beta 
adrenoreceptor antagonists. 
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Disturbance of cardiac impulse generation and conduction in the 
presence of pre existing SA and AV node disease can lead to symptomatic 
bradycardia and impairment of atrio ventricular (AV) nodal conduction 
(Wenkebach phenomenon, AV dissociation) which have been occasionally 
described. 
PREPARATIONS 
Oral forms 
1.  Catapres tablets (Boehringer Ingeiheirn, UK) containing clonidine 
hydrochloride l00 µg, 200 µg or 300 µg. 
2.  Dixarit tablets (Boehringer Ingeiheim, UK) containing clonidine 
hydrochloride 25 µg. 
Transdermal form 
  Catapres TTS delivering clonidine l00 µg, 200 µg or 300 µg daily for 
1 week. 
Parenteral form 
1. Catapres injection (Boehringer Ingeiheim, UK) containing clonidine 
hydrochloride 150 µg/ml ampoules 
2. CLONEON (Neon labs ltd, thane) containing clonidine 
hydrochloride 150 µg/ml ampoule. 
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PHARMACOLOGY OF DEXMEDETOMIDINE 
      Dexmedetomidine hydrochloride is a 4-((s)-alpha,2,3-trimethyl 
benzyl) imidazole monohydrochloride or 4-[(1r)-1-(2,3-dimethylphenyl) 
ethyl]-3h-imidazole hydrochloride. 
 
Molecular weight-236.74   
Dexmedetomidine 
is a new alpha 2-agonist used as a 
short-term (less than 24 h) sedative 
analgesic in the intensive care unit. 
When compared to Clonidine is a much 
more selective alpha 2-adrenoceptor agonist, the alpha2/alpha1 selectivity of 
dexmedetomidine is 1620 and hence is 8 times more powerful alpha2-
adrenoceptor than clonidine. In addition, dexmedetomidine is shorter-acting 
drug than clonidine and has a reversal drug for its sedative effect, 
atipamezole. These properties render dexmedetomidine suitable for sedation 
and analgesia during the whole perioperative period: as premedication, as an 
anesthetic adjunct for general and regional anesthesia, and as postoperative 
sedative and analgesic. 
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Alpha2-receptors are found in many sites throughout the body. 
Alpha2-adrenoceptors are found in peripheral and central nervous systems, 
in effector organs such as the liver, kidney, pancreas, eye, vascular smooth 
muscles and platelets. Alpha2-adrenoceptors are divided into three 
subthypes:  the subtype a, the predominant subtype in central nervous 
system, is responsible for the sedative, 
analgesic and sympatholytic effect; the 
subtype b, found mainly in the peripheral 
vasculature, is responsible for the short-
term hypertensive response, and the 
subtype c, found in the central nervous 
system, is responsible for the anxiolytic effect. 
Pharmacodynamics of dexmedetomidine 
  The highest densities of alpha2- receptors are found in the locus 
ceruleus, the predominant noradrenergic nuclei of the brainstem and an 
important modulator of vigilance. Presynaptic activation of the alpha2-a 
adrenoceptor in the locus ceruleus inhibits the release of norepinephrine and 
results in the sedative and hypnotic effects in addition, the locus ceruleus is 
the site of origin for the descending medullospinal noradrenergic pathway, 
known to be an important modulator of nociceptive neurotransmission. 
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           Stimulation of the alpha2-adrenoceptors in this area terminates the 
propagation of pain signals leading to analgesia. Postsynaptic activation of 
alpha2-adrenoceptors in the CNS results in decrease in sympathetic activity 
leading to hypotension and bradycardia. At the spinal cord, stimulation of 
alpha2-receptors at the substantia gelatinosa of the dorsal horn leads to 
inhibition of the firing of nociceptive neurons and inhibition of the release 
of substance P. Also, the alpha2-adrenoceptors located at the nerve endings 
have a possible role in the analgesic mechanisms of alpha2-agonists by 
preventing noradrenaline release. 
Pharmacokinetics of Dexmedetomidine 
Dexmedetomidine, an imidazole compound, is the active d-isomer of 
medetomidine. Following intravenous administration, dexmedetomidine 
exhibits the following pharmacokinetic parameters: a rapid distribution 
phase with distribution half-life (t ½ α) of 6 minutes; elimination half-life (t 
½ β) of 2 hours;  volume of distribution (vss) 118 litres. Dexmedetomidine 
exhibits linear kinetics when infused in the dose range of 0.2-0.7 
micrograms/kg/h for not more than 24 hours. Dexmedetomidine undergoes 
almost complete biotransformation through direct glucuronidation and 
cytochrome p450 metabolism. Metabolites of biotransformation are 
excreted in the urine (95%) and feaces. The average protein binding of 
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dexmedetomidine is 94%. Dexmedetomidine is a white powder that is freely 
soluble in water and pKa of 7.1. 
Dosage 
It is supplied as 100 µg/ml, 2 ml vial which must be diluted with 48 
ml of 0.9% sodium chloride solution prior to administration. For adult 
patient, dexmedetomidine is administered by a loading infusion of 0.5-1 
µg/kg over 10 minutes, followed by a maintenance infusion of 0.2 to 0.7 
µg/kg/hr. The effect appears in 5-10 minutes, and is reduced in 30-60 
minutes. The maintenance infusion is adjusted to achieve the desired level 
of sedation. 
Perioperative uses of dexmedetomidine 
i) Premedication 
              Dexmedetomidine possesses anxiolytic, sedative, analgesic, 
antisialogogue and sympatholytic properties.  Intramuscular 
dexmedetomidine at a dose of 1 µg/kg is used for premedication. 
ii) Intraoperative uses of dexmedetomidine 
Intraoperative uses of dexmedetomidine include its use as adjunct to 
general anesthesia, as adjunct to regional anesthesia, in monitored 
anesthesia care (MAC), or as a sole agent for total intravenous anesthesia 
(TIVA). 
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iii) Use of dexmedetomidine in the postoperative period 
     Dexmedetomidine’s special properties favour its use in the recovery 
room. In addition to its sympatholytic effects, analgesic effects, decreased 
rate of shivering and the preservation of respiratory function allows the 
continuation of the dexmedetomidine infusion in the extubated, 
spontaneously breathing patient. The possibility of ongoing sedation and 
sympathetic block could be beneficial in reducing high rates of early 
postoperative ischemic events in high-risk patients undergoing non-cardiac 
surgery. 
Contraindication 
i) Pre-existent severe bradycardia and conduction problems.  
ii)  In patients with reduced ventricular functions (ejection 
fraction<30%) 
iii) In patients who are hypovolemic or hypotensive. 
Adverse effects  
           The common adverse effects of dexmedetomidine include 
hypotension, hypertension, nausea, bradycardia, atrial fibrillation, hypoxia 
and various atrioventricular blocks.  
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ASSESSMENT OF BLOCKADE AFTER SPINAL 
ANAESTHESIA 
Following subarachnoid block assessment of motor & sensory block 
is done in the following manner. 
SENSORY BLOCK 
Sensory block was assessed by loss of sensation to pinprick using 
23G sterile needle. The assessment was started immediately after injection 
and continued every 30 secs till loss of pinprick sensation at T10 level. 
Onset of sensory block was taken as time from intrathecal injection to loss 
of pinprick sensation atT10. At regular interval after SAB , the dermatomal 
level of sensory block was assessed till a maximum level of sensory block 
was attained. 
MOTOR BLOCK 
Motor block was assessed using modified BROMAGE score: The 
motor block was assessed according to the modified Bromage scale (8):  
1. Bromage 0 -  the patient is able to move the hip, knee and ankle 
2. Bromage 1 - the patient is unable to move the hip but is able to 
move the knee and ankle 
3. Bromage 2 - the patient is unable to move the hip and knee but 
able to move the ankle 
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4. Bromage 3 - the patient is unable to move the hip, knee and 
ankle. 
Assessment of motor block was started immediately after the 
intrathecal injection. It was tested every min till BROMAGE SCORE of 3 
was reached. Onset of motor block was taken as time taken to achieve 
BROMAGE score of 3 from Subarachnoid block. The degree of motor 
block after 20mins of injection was noted and this was considered maximum 
degree of motor block. Thereafter motor block regression was noted and 
duration of motor block was taken as time from SA injection to return of 
BROMAGE score to 0 
ASSESMENT OF SEDATION AND PAIN:  
Sedation was assessed using Ramsay sedation score and pain was 
assessed using visual analogue scale:  
Ramsay Sedation Score : 
1 Anxious, agitated or restless 
2 Co-operative, oriented, tranquil but alert 
3 Responds to command 
4  Asleep but brisk response to glabellar tap or loud auditory 
stimuli 
5 Asleep, sluggish response to glabellar tap or auditory stimuli 
6 Asleep, no sleep response 
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REVIEW OF LITERATURE 
Clonidine combined with local anaesthetics in spinal anaesthesia 
Van tuiijl et al., 
34
 investigated the effect of addition of clonidine to 
hyperbaric bupivacaine on post operative morphine consumption after 
caessarian section. 
A group of 106 patients were randomly allocated to receive spinal 
anaesthesia with either 2.2 ml of 0.5% bupivacaine heavy with 0.5ml NS 
0.9% total 2.7 ml (Gp B) or to receive 2.2 ml of 0.5% bupivacaine heavy 
with clonidine 0.5 m1-75 µg diluted in 0.9% NS total of 2.7 ml (Gp BC). 
The time for first analgesic request was 129 mins in the BC gp compared to 
55 mins in the B gp. In the BC gp 58% had a MAP <70 mmHg compared to 
9% in gp B. Clonidin added to bupivacaine in caessarian section prolongs 
the duration of analgesia and motor block. It did not result in reduced 
morphine consumption in the first post operative day. 
Wu  et a1.,
32 
 studied the effect of adding clonidine to hyperbaric 
tetracaine spinal anaesthesia in 60 ASA class I - II patients .The subjects 
were randomly allotted to 4 groups. All patients received tetracaine 10 mg 
in 10% glucose solution 2 ml. Patients in group I received the above 
medication and were the control group, patients in other group received 
tetracaine plus increasing doses of clonidine: 15 µg (gp 2) ,30 µg (gp 3) and 
45 µg (gp 4). The three clonidine groups had significant increase in sensory 
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regression time to L1 level ( by 42 ,47 , 60%, respectively) and also had 
significantly increased motor complete recovery time, but the incidence of 
hypotension and bradycardia was increased in clonidine 45 µg group. He 
concluded that addition of l5 µg or 30 µg may be useful as a means of 
increasing the duration of hyperbaric tetracaine spinal anaesthesia. 
Niemi studied the analgesic and circulatory effects of intrathecal 
clonidine in patients undergoing knee arthroscopy under spinal anaesthesia. 
Forty ASA I and II patients were randomly divided into 2 group. One group 
received clonidine 3µg/kg mixed with 0.5% bupivacaine and the other 
group an identical saline volume mixed with bupivacaine as above in a 
double blinded fashion. Oxycodone 0.14 mg/kg i.m or ketoprofen 100 mg 
p.o was administered when needed. The duration of sensory analgesia, was 
longer in clonidine group (mean 215 mins) than in control group (mean 160 
mins) (p<0.05). Duration of motor blockade was also longer in clonidine 
group (mean 161 mins) (p<0.05). Mean arterial pressure and heart rate were 
significantly lower in the clonidine group compared to control group. More 
patients in the clonidine group were sedated 3-6 hrs after the injection 
(p<0.05). Addition of clonidine prolonged the bupivacaine spinal block. 
De Negri et al., studied to determine whether intrathecal 
administration of clonidine can reduce the dose of local anesthetic, and the 
effects of clonidine on cardiovascular system and on arousal level. In 56 
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patients scheduled for minor surgical procedure (spermatic vein ligature) 
under unilateral spinal anesthesia with hyperbaric bupivacaine 1% one half 
of patients received clonidine 150 µg in addition to bupivacaine.  Cardiac 
output, stroke volume, ejection fraction were measured by thoracic electric 
bio impedance method, baseline and until 1 h after surgery. In clonidine 
treated group, variations of cardiovascular parameters were observed, in the 
same group sensory block, motor block were significantly prolonged. A 
higher sedation level and a significant post operative analgesia were also 
observed. The addition of clonidine to hyperbaric bupivacaine seems to be 
particularly useful in unilateral spinal anesthesia, exerting minimal influence 
on hernodynamic parameters and guaranteeing a satisfactory postoperative 
analgesia. 
Seah et al., studied the prolongation of analgesic effect of hyperbaric 
bupivacaine spinal anesthesia with clonidine. 40 AS A class I & II patients 
scheduled for TTJRP were randomly classified into 2 groups of 20 each. In 
the saline group, 3 m1 of 0.5% hyperbaric bupivacaine + 1ml NS was given. 
In the clonidine group, 1ml of (150 µg) clonidine in addition to 3 ml of 
0.5% bupivacaine was given. The mean time for two segment regression to 
L2 was significantly greater in clonidine group than in the saline group. 
Motor block was also prolonged in the clonidine group than in the saline 
group. Side effects such as hypotension and bradycardia commonly 
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occurred in clonidine group, but all patients could be effectively treated with 
ephedrine and atropine, respectively. 
Clonidine as sole analgesic in spinal anaesthesia 
Fibs kritonl
 
et al.
 4
 studied to evaluate the effect of intrathecal 
clonidine as the sole analgesic on pain following caessarian section. Twenty 
patients who underwent elective caessarian section receive 45 mins after 
GA either 150 µg clonidine (n=10) or saline (n=10) intrathecally. Pain 
scores were lower in clonidine than saline treated patients. Pain relief in 
terms of the first supplemental analgesic requested by patients lasted 414 
mins after clonidine and 181 mins after saline. The results suggest that 150 
µg clonidine is effective in pain following caessarian section but is not free 
of side effects like hypotension, sedation and dryness of mouth. 
Goudas Leonidas et al. 
19
 studied to evaluate the dose response 
hemodynamics and analgesic profiles of intrathecal clonidine. 30 women 
who underwent LSCS under GA 45 mins after tracheal extubation, a lumbar 
puncture was performed and patients received 150 µg (gp 1) ,300µg 2) and 
450µg (gp 3) clonidine. Pain relief lasted 402 ±75 mins in group 1,570+ 76 
mins in gp 2, 864± 80 mins in gp 3 . Sedation was found in all three groups. 
The results demonstrated dose dependent analgesia after intrathecal 
clonidine at doses as great as 450 µg .A relative hemodynamic stability is 
suggesting a pressor effect at peripheral sites. 
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Clonidine combined with opioids and local anesthetics in spinal 
anesthesia 
Chiari astrid et al.
7
 evaluated the dose response potency of 
intrathecally administered Clonidine during 1
st
 stage of labour along with 
Sufentanil. 36 parturients received 50 µg, 100 µg and 200 µg of intrathecal 
clonidine. 
The duration of analgesia was significantly more in 200 µg gp. 
Duration and quality of analgesia were more pronounced in 100 µg, 200 µg 
than with 50 µg. The high incidence of hypotension requires caution with 
use of 200 µg for labour analgesia. 
Gautier Philippe et al.
20
 studied the efficacy of low doses of 
intrathecal Clonidine (15 µg & 30 µg) combined with sufentanil. 93 
parturients received one of the following intrathecal solutions, either 15 µg 
clonidine (n=10), 30 µg clonidine (n=10), 2.5 µg sufentanil and 15 µg 
clonidine (n=13), and 5 µg sufentanil with 30 µg clonidine (n=13). Patients 
receiving 30 µg intrathecal clonidine with 2.5 or 5 µg sufentanil had 
significantly long lasting analgesia. 30 µg intrathecal clonidine with 2.5 or 5 
µg intrathecal sufentanil had significantly increased the duration of 
analgesia during the first stage of labour without adverse maternal or fetal 
effects. 
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Benhamou Dan et a1.
2
 studied 78 pregnant women at term scheduled 
for, elective caessarian section to compare the analgesic efficacy and side 
effect profile of a spinal block with hyperbaric bupivacaine alone (group B) 
or combined with 75 µg clonidine (group BC) or with clonidine 75 µg and 
fentanyl 12.5 µg (group BCF). Adding a small dose of intrathecal clonidine 
to bupivacaine increases the quality of intraoperative analgesia and 
decreases pain during cesarian section. Combining clonidine with fentanyl 
further improved analgesia. 
Acalovschi lurie et al.
1
 studied the effects of intrathecally 
administered epinephrine and clonidine on the duration and quality of 
meperidine spinal block. 45 patients scheduled for orthopaedic surgery 
divided into 3 groups, received spinal anaesthesia with 1 mg/kg meperidine 
5% alone or with 200 µg epinephrine or 2 µg/kg clonidine. 
The duration and degree of motor block were increased by addition of 
both epinephrine and clonidine. A tendency toward bradycardia and 
decrease in MAP was potentiated by clonidine. The co administration of 
clonidine or epinephrine with meperidine enhances the duration and degree 
of spinal anaesthesia and that adding clonidine prolongs duration of post 
operative analgesia. 
Owen et al.
30
 studied to determine whether the addition of clonidine 
and neostigmine to intrathecal bupivacine fentanyl would increase the 
 
48
duration of analgesia without increasing side effects for patients in labour. 
45 healthy parturients in active labour received 2 m1 intrathecal dose of one 
of the following dextrose containing solutions: 1. Bupivacaine 2.5 mg and 
fentanyl 25 µg (BF) 2. BF + Clonidine 30 µg 3. BFC + neostigmine 10 µg 
(BFCN). Patients administered BFCN had significantly longer analgesia 
(165 + 32 mins) than those who received BF (90 +21 mins) or BFC (123±21 
mins) p<0.001. The addition of clonidine and neostigmine significantly 
increased the duration of analgesia but neostigmine caused more nausea. 
Dexmedetomidine compared with Clonidine/opioids and local 
anesthetics in spinal anesthesia 
Intravenous Dexmedetoniidine vs. Intravenous Clonidine to prolong 
Bupivacaine Spinal Anesthesia. A Double Blind Study by Victor ‘Whizar et 
al. – intravenous Dexmedetomidine as well as intravenous clonidine given 
after spinal bupivacaine anesthesia was able to prolong anesthesia compared 
to placebo. Initial dexmedetomidine mean dose was 70±7.5 µg, and mean 
maintenance dose 34+4 µg/kg/h. Clonidine mean dose was 268±32 µg. 
Sensory block duration was longer in D and C groups, 208±43.5 and 
225±58.8 min respectively, vs. placebo group 137±121.9 min (P=0.05). 
Motor block duration was longer in Group D and C (191±49.8 and 
172±36.4) vs. placebo group (172±36.4) without significant statistical 
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difference. Hemodynamic changes (bradycardia, hypotension) were similar 
in all groups and without clinical relevance. 
Effect of Adding Dexmedetomidine vs. Fentanyl to Intrathecal 
Bupivacaine on Spinal Block Characteristics in gynecological Procedures: 
A Double Blind Controlled Study- Subhi M. Al-Ghanem et al. studied 76 
patients scheduled for vaginal hysterectomy. They receive intrathecally 
either 10 mg isobaric bupivacaine plus 5 µg dexmetedomidine (group D, 
n=38) or 10 mg isobaric bupivacaine + 25 µg fentanyl (group F, n=38), the 
onset time to reach peak sensory and motor level, the regression time for 
sensory and motor block, hemodynamic changes and side effects were 
recorded. 5 µg dexmetedomidine produces prolonged motor and sensory 
block compared with 25 µg fentanyl. Patients in group D had significant 
longer sensory and motor block. The mean time of sensory regression to S1 
was 274±73 min in group D and 179±47 min in F (P < 0.00 1). The 
regression time of motor block to reach modified Bromage 0 was 240±60 
min in D and 155+46 min in F (P < 0.00 1). The onset times to reach 110 
dermatorne and to reach peak sensory as well as onset time to reach 
modified Bromage 3 motor block were not significantly different between 
the two groups. 
Effect of dexmedetomidine added to spinal bupivacaine for urological 
procedures - Mahmoud M. Al-Mustafa et al. - Dexmedetomidine has a dose 
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dependant effect on the onset and regression of sensory and motor block 
when used as an adjuvant to bupivacaine in spinal anesthesia. Sixty-six 
patients were into 3 groups, each receiving spinal bupivacaine 12.5 mg 
combined with normal saline (group N), Dexmedetomidine 5 µg (group 
D5), or dexmedetomidine 10 µg (group D10). The onset times to reach T10 
sensory and Bromage 3 motor block, and the regression times to reach S1 
sensory level and Bromage 0 motor scale, were recorded: The mean time of 
sensor block to reach the T10 dermatome was 4.7±2.0 mins in D10 group, 
6.3±2.7 mins in D5, and 9.5±3.0 mins in group N. The mean time to reach 
Brornage 3 scale was 10.4±3.4 mins in group Dl0, 13.0±3.4 mins in D5 and 
18.0±3.3 mins in group N. The regression time to reach S1 dermatome was 
338.9+44.8 mins in group D10, 277.1+23.2 mins in D5 and 165.5+32.9 
mins in group N. The regression to Bromage 0 was 302.9±36.7 mins 
246±25 mins in D5 and 140±32 mins in N. 
Effect of low-dose dexmedetomidine or clonidine on the 
characteristics of bupivacaine spinal block by Kanazi et al. - 
Dexmedetomidine (3 µg) or clonidine (30 µg), when added to intrathecal 
bupivacaine, produces a similar prolongation in the duration of the motor 
and sensory block with preserved hemodynamic stability and lack of 
sedation. 60 patients undergoing transurethral resection of prostate or 
bladder tumor under spinal anesthesia were randomly allocated to one of 
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three groups. Group B received 12 mg of hyperbaric bupivacaine, D 
received 12 mg of bupivacaine supplemented with 3 µg of 
dexmedetomidine and group C received 12 mg of bupivacaine 
supplemented with 30 µg of clonidine. Patients in groups D and C had a 
significantly shorter onset time of motor block and significantly longer 
sensory and motor regression times than patients in B. The mean time of 
sensory regression to the S1 segment was 303±75 min in group D, 272±38 
min in C and 190±48 min in group B (B vs. D and B vs. C, P < 0.001). The 
regression of motor block to Bromage 0 was 250 ±76 min in group D, 
216±35 mm in group C and 163 ± 47 min in group B (B vs. D and B vs. C, 
P < 0.00 1). The onset and regression times were not significantly different 
between groups D and C. The MAP, heart rate and level of sedation were 
similar in the three groups intra-operatively and post operatively. 
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MATERIALS AND METHODS 
This study was conducted at Madurai Medical College Hospital, 
Madurai between March 2011 to August 2011 on 94 patients of ASA 
physical status I, II and III undergoing infra umbilical surgeries. 
This study was done after Ethical Committee approval and written 
informed consent obtained from all patients included in the study. 
STUDY DESIGN 
This study was done in a prospective double blinded randomized 
manner. 
SELECTION OF CASES 
Inclusion criteria 
• Patients in age group of 18 to 70 yrs 
• ASA - PS I, II and III 
• Infra umbilical surgeries 
Exclusion criteria 
• ASA - PS IV 
• Patient refusal 
• Renal/ hepatic disfunction  
• Allergic to the drugs 
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• Contra indication to subarachnoid block 
• Labile hypertension, arrhythmias, currently on anti hypertensive 
therapy 
94 patients were included in this double blinded randomized 
controlled study.  
Patients were divided into 3 groups.  
Patients in group B received 2.5ml of 0.5% hyperbaric bupivacaine 
plus 0.5ml preservative free  normal saline.  
Patients in group C received 2.5ml of hyperbaric bupivacaine with 50 
µg of clonidine in 0.5 ml preservative free normal saline.  
Patients in group D received 2.5ml of hyperbaric bupivacaine 
with5µg of dexmedetomidine in 0.5 ml preservative free normal saline. 
Pre Anaesthetic Evaluation 
Patients included in the study underwent thorough pre operative 
evaluation which included the following 
History 
History of underlying medical illness, previous surgery, anesthesia 
and hospitalization. 
Physical examination 
1. GC of the patient 
2. Vital signs 
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3. Height and weight 
4. Examination of CVS, RS, CNS and vertebral columns 
5. Airway assessment 
Investigations 
Hb, PCV, BT, CT, RFT, blood sugar, ECG, CXR, platelet count, 
blood grouping and cross matching were done. Patients who satisfied the 
inclusion criteria were explained about the nature of the study and the 
anesthetic procedure. Written informed consent was obtained from all 
patients included in the study. 
HOW DOUBLE BLINDING WAS DONE 
Allotment of cases was done by table of random numbers. The 
Consultant who made the drug combination took no further part in the 
study. I performed the subarachnoid block and noted the observations both 
intra-operatively and post-operatively. 
Technique 
In the OT, appropriate equipment for airway management and 
emergency drugs were kept ready. No premedication were given prior to the 
surgery. The horizontal position of the operating table was checked and 
patient shifted to the table. I.V. line was secured and preloaded with 500 ml 
Ringer lactate solution. NIBP, Sp02 were connected to the patient. 
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Preoperative baseline systolic and diastolic BP, PR, Sp02 and RR were 
recorded. SAB was done and observations were made in all the patients 
involved in the study. Under strict aseptic precautions a midline lumbar 
puncture was performed using a 24/25G Quincke needle in sitting 
position/right lateral decubitus position. The patient was then immediately 
placed in supine position. Lumbar puncture was successful in first attempt 
in almost all the patients. Vital signs were recorded at 5 mins interval 
intraoperativel until the end of surgery. In the recovery room vital signs 
were recorded every 15 mins. The sensory block level was assessed by 
pinprick sensation using a 25 guage needle along the midclavicular line 
bilaterally. The motor block was assessed according to the modified 
Bromage scale (8): Bromage 0, the patient is able to move the hip, knee and 
ankle; Bromage 1 the patient is unable to move the hip but is able to move 
the knee and ankle; Bromage 2, the patient is unable to move the hip and 
knee but able to move the ankle; Bromage 3, the patient is unable to move 
the hip, knee and ankle. The times to reach T10 dermatorne sensory block 
peak sensory level and Bromage 3 motor block were recorded during 
surgery. The regression time for sensory and motor block were recorded in 
recovery room. All durations were calculated considering the time of spinal 
injection as time zero. Patients were discharged from the recovery room 
after sensory regression to S1 dermatome and Bromage 0 was attained. 
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Assessment of pain intra-operatively was done using visual analogue pain 
scale between 0-10 (0 = no pain, 10 = the most severe pain). 
Intraoperative nausea, vomiting, pruritus, additive analgesia and 
sedation were recorded. T1 sedation was assessed using Ramsay Sedation 
Score. 
1 Anxious, agitated or restless 
2 Co-operative, oriented, tranquil but alert 
3 Responds to command 
4  Asleep but brisk response to glabellar tap or loud auditory stimuli 
5 Asleep, sluggish response to glabellar tap or auditory stimuli 
6 Asleep, no sleep response 
The time for intrathecal injection was considered as 0 and the 
following parameters were observed - sensory blockade and motor 
blockade, duration of analgesia and sedation. 
Vital signs and side effects 
The PR, systolic and diastolic BP, Sp02 and RR were recorded for 
every 5 mins till one hour and then every 10 mins throughout the intra 
operative period. 
Hypotension defined as fall in systolic BP > 30% from baseline or 
SBP < 90 mmHg. This was managed with inj. Ephedrine 6 mg and a bolus 
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administration of 250 ml of RL solution over 10 mins. The above was 
repeated if BP remained low. 
Bradycardia was defined as HR < 50/min and this was managed with 
inj. atropine 0.3 to 0.6 mg i.v. 
Respiratory depression defined as RR< 8/min and or Sp02 < 85%. 
This was planned to be managed with bag and mask ventilation or 
intubation and IPPV if necessary. Blood loss more than the allowable loss 
was replaced with blood. 
Assessment in Recovery Room 
Patient was shifted to recovery room after completion of surgery, the 
vital signs, sensory and motor blockade assessment were recorded, every 15 
mins till a Bromage 0 and a sensory regression to S1 dermatorne was 
obtained. After the above were attained, the patients were shifted to post 
operative ward.  
Assessment of pain and duration of 
analgesia 
In the recovery room pain 
assessment using VAS were done 
every 15 mins. At the end of surgery, 
the degree of pain was assessed using 
VAS scale till VAS score >/= 4 was reached. Whenever the patient 
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complained of pain a rescue analgesic (Inj. Diclofenac 75 mg i.m) was 
given. Duration of effective analgesia was defined as time interval between 
onset of SAB and the time to reach VAS >/=4. 
Patients were monitored for 24 hrs to detect the occurence of side 
effects - respiratory depression, nausea, vomiting, dry mouth and pruritis. 
Patients were also enquired about the occurence of Transient neurological 
symptoms which was described as pain / paresthesia in the neck, buttocks, 
legs or pain radiating to lower extremities after initial recovery from SAB 
within 72 hrs.  
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OBSERVATIONS & RESULTS 
Statistical analysis 
All recorded data were entered using MS Excel software and analysed 
using SPSS ver.16 software for determining the statistical significance. 
Results are expressed as the means and standard deviations, medians and 
ranges, or numbers and percentages. The comparison of normally 
distributed continuous variables between the groups were performed using 
one-way Analysis of variance (ANOVA) and, if appropriate, followed by 
the Bonferroni’s test for post hoc analysis. Nominal categorical data 
between study groups were compared using the chi-squared test or Fisher’s 
exact test as appropriate. Ordinal categorical variables and non-normally 
distributed continuous variables were compared using Mann—Whitney U-
test. P < 0.05 was considered to be significant. 
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DEMOGRAPHICS 
 
Table 1 
Demography 
 
N Mean 
Std. 
Deviation F Sig. 
Age (yrs) Bupivacaine 33 42.85 9.856 
.35 P<0.70 
Clonidine 33 41.21 8.749 
Dexmedetomedine 28 43.29 12.186 
Total 94 42.40 10.183 
Weight(kg) Bupivacaine 33 55.67 8.061 
0.427 P<0.654 
Clonidine 33 54.00 7.331 
Dexmedetomedine 28 55.82 10.760 
Total 94 55.13 8.670 
Height(cms) Bupivacaine 33 160.70 5.817 
2.146 P<0.123 
Clonidine 33 158.45 7.045 
Dexmedetomedine 28 161.86 6.824 
Total 94 160.26 6.651 
 
 
One way ANOVA  and t test shows no significant difference among 
the all three groups in terms of demography variable like Age, Height and 
Weight. (Suggesting comparability between the groups) 
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Table  2: ASA Physical Status Among The Groups 
 ASA status 
Total ASA 1 ASA 2 ASA 3 
Bupivacaine 24 9 0 33 
72.7% 27.3% .0% 100.0% 
Clonidine 21 12 0 33 
63.6% 36.4% .0% 100.0% 
Dexmedetom
edine 
17 10 1 28 
60.7% 35.7% 3.6% 100.0% 
Total 62 31 1 94 
66.0% 33.0% 1.1% 100.0% 
 
Pearsons 
chi(X
2
) square 
test : p<0.532. 
All three groups 
are comparable 
by ASA Status 
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Table 3: Sex Distribution Among Groups 
 
 Gender 
Total Female Male 
group B 8 25 33 
24.2% 75.8% 100.0% 
C 7 26 33 
21.2% 78.8% 100.0% 
D 5 23 28 
17.9% 82.1% 100.0% 
Total 20 74 94 
21.3% 78.7% 100.0% 
 
Pearsons 
chi(X
2
) square 
test: p < 0.832. 
The groups are 
comparable by sex 
distribution.  
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4. DURATION OF SURGERY 
PARAMETERS GROUP B GROUP C GROUP D ANOVA 
NO.OF CASES 33 33 28  
P =0.37 MEAN 91.7 100.8 91.9 
S.D. 24.95 32.5 28.36 
The mean duration of surgery is higher in Group C when compare to 
other two groups.  But this is of no statistical significance. 
 
5.  TYPE OF SURGERY BY GROUPS 
 
 
SURGERY GROUP B GROUP C GROUP D 
Inguinal hernial Repair 22 
66.7% 
19 
57.6% 
15 
53.6% 
Appendicectomy 0 
.0% 
6 
18.2% 
4 
14.3% 
Varicose vein Sx 0 
.0% 
1 
3.0% 
2 
7.1% 
APR 3 
9.1% 
1 
3.0% 
2 
7.1% 
Gynaecological 2 
6.1% 
1 
3.0% 
1 
3.6% 
Orchidopexy/hydrocoele 1 
3.0% 
0 
.0% 
3 
10.7% 
Incisional Hernial 
Repair 
1 
3.0% 
4 
12.1% 
0 
.0% 
Urology(DJ stent/Open 
Urethrotomy) 
3 
9.1% 
1 
3.0% 
0 
.0% 
others 1 
3.0% 
0 
.0% 
1 
3.6% 
 
Pearsons CHI square test shows no significant difference in the surgeries 
performed between the study groups (p<0.80) 
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6. DISTRIBUTION OF MEAN ONSET OF SENSORY BLOCK 
(Mins) BY GROUPS 
PARAMETERS GROUP B GROUP C GROUP D ANOVA 
No. of cases 33 33 28  
p-<0.0001 
Mean 6.35 4.031 3.35 
S.D 10.809 43.542 32.23577 
There is a significant 
difference between groups 
with regard to onset of 
sensory block with group D 
having a rapid onset 
compared to C. Both group 
C&D have significant early 
onset of sensory blockade 
than group B. The onset of 
sensory blockade is 
significantly faster for 
Dexmedetomidine than 
clonidine confirmed by Post 
Hoc test( bonferroni’s test) 
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7. DISTRIBUTION OF MEAN ONSET OF MOTOR BLOCK 
(Mins) BY GROUPS 
PARAMETERS GROUP B GROUP C GROUP D ANOVA 
No. Of cases 33 33 28 <0.0001 
Mean(min) 7.38 3.88 3.28 
S.D 1.251 1.040 1.1109 
Post Hoc Analysis(Bonferroni) No difference between 
C&D( P>0.072) 
 
There is a shorter onset of motor block in group dexmedetomidine and 
clonidine Vs. bupivacaine group which is statistically significant. But post hoc 
analysis demonstrate no significant difference in the onset of motor blockade 
between dexmeditomidine and  clonidine groups (bonferroni Post Hoc analysis- p 
>0.072). 
 
8. DISTRIBUTION OF MAX. SENSORY BLOCK AMONG GROUPS 
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PARAMETERS GROUP B GROUP C GROUP D 
 NO % NO % NO % 
T2 0 0 0 0 4 14.2 
T3 0 0 2 6.6 5 17.9 
T4 0 0 11 36.6 10 35.7 
T5 4 13.2 6 19.8 6 21.5 
T6 9 29.7 13 42.9 3 10.7 
T7 7 23.1 2 6.6 0 0 
T8 8 26.4 0 0 0 0 
T9 4 13.2 0 0 0 0 
T10 1 3.3 0 0 0 0 
TOTAL 33 100 33 100 28 100 
              The  median and range of the peak sensory level 
reached were T7 (T5–T10) in group B, T5 (T3–T7) in group C and T4 (T2–
T6) in group D, with significant differences between the three groups even 
Clonidine and Dexmedetomidine( non parametric test- Kruskal Wallis rank 
test-P =0.002) 
 
9.  DISTRIBUTION OF CASE BY GROUPS AND GRADE OF 
MAXIMUM MOTOR BLOCK 
 
 
PARAMETERS GROUP B GROUP C GROUP D 
No. Of cases 33 33 28 
Mean 4 4 4 
S.D 0 0 0 
There is no difference between the groups in the grade of maximum motor 
block. 
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10.  DISTRIBUTION OF MEAN TWO SEGMENTAL 
REGRESSION (mins) BY GROUPS 
 
 
PARAMETERS GROUP B GROUP C GROUP D ANOVA 
No. Of cases 33 33 28  
P<0.001 
Mean 77 99.53 136.55 
S.D 8.24 16.6 11.8 
 
 
There is a significant difference in the two segemental regression with 
Group D having a much prolonged duration of regression than B and C 
which of statistical significance both by ANOVA and Bonferroni test. 
 
11.  DISTRIBUTION OF MEAN DURATION OF MOTOR 
 
BLOCK (mins ) BY GROUPS 
PARAMETERS GROUP B GROUP C GROUP D ANOVA 
No. Of cases 33 33 28  
P<0.0001 
Mean 148.55 205.9 262.41 
S.D 13.848 12.904 16.693 
There is a significant difference between the groups interms of total duration 
of Motor blockade with Group D having much longer duration blockade 
than Group C and B. (By ANOVA and Bonferroni post hoc) 
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12  DISTRIBUTION OF MEAN DURATION OF ANALGESIA 
BY GROUPS 
PARAMETERS GROUP B GROUP C GROUP D ANOVA 
No. Of cases 33 33 28  
P< 0.001 
Mean 115.97 305.8 366.03 
S.D 9.215 17.341 28.635 
 
 
There is a significant 
difference between the 
groups interms of total 
duration of Analgesia with 
Group D having much 
longer duration than Group 
C and B 
 
 
 
 
 
 
 
 
 
 
 
13   DISTRIBUTION 
OF MEAN 
DURATION OF 
SENSORY 
BLOCKADE BY 
GROUPS 
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Table:13  Total Duration  Of Sensory Block( Time to S1 regression) 
PARAMETERS GROUP B GROUP C GROUP D ANOVA 
No. Of cases 33 33 28  
P<0.0001 
Mean 179.84 265.47 337.97 
S.D 14.22 17.28 22.45 
 
There is a significant difference between the groups in terms of total 
duration of Sensory Block with Group D having much longer duration than 
Group C and B (By ANOVA and Bonferroni post hoc - p < 0.001.) 
 
14.   DISTRIBUTION OF SIDE EFFECTS 
EFFECTS GROUP B GROUP C GROUP D 
 NO % NO % NO % 
HYPOTENSION 2 10 1 5 2 10 
BRADYCARDIA 1 5 1 5 2 10 
SEDATION 0 0 10 50 20 100 
DRYNESS OF 
MOUTH 
0 0 1 5 2 10 
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DISCUSSION 
Alpha 2 agonist clonidine and dexmedetomidine, when added to local 
anaesthetics in sub-arachnoid block have shown to provide excellent 
surgical anaesthesia. 
ONSET OF SENSORY BLOCK: 
In my study, the mean time to onset of sensory block was 6.35 mins 
in group B and 4.03mins in group C and 3.35mins in group D. Both groups 
C&D have significant early onset of sensory blockade than group B, with 
Group D having a much rapid onset compared to group C.  
Al-Mustafa et al41,43 studied intrathecally administered 5µgms 
Dexmedetomidine combined with 0.5% Bupivacaine 12.5mg vs  
Bupivacaine 12.5mg alone. The sensory blockade onset time were 6.3 and 
9.5mins respectively, which is similar to our study. But the delayed onset in 
sensory blockade in their study might have been due to SAB being 
performed in sitting position. 
ONSET OF MOTOR BLOCK: 
The mean time to onset of motor block was 7.3min in group B, 3.9 
min group C and 3.3min in group D. The addition of dexmedetomidine and 
clonidine has significantly shortened the time to onset of motor blockade in 
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our study. Even though dexmedetomidine quickens the motor blockade than 
clonidine, it seems to be statistically insignificant (Post Hoc analysis doesn’t 
show any significant difference between Group C&D (Bonferroni- 
p>O.072)). 
Al mustafa et al41,43  demonstrated similar findings in his study(Group 
B 8min, C-13 min, D-10 min). But the delayed onset in their study might be 
due to SAB being performed in sitting position. 
MAXIMUM LEVEL OF SENSORY BLOCK: 
There was a statistically significant difference among the groups in 
maximum level of sensory block. Median and range of Highest Sensory 
blockade attained were; Group B- T7 (T5-T1O), GroupC- T5 (T3-T7), 
GroupD- T4 (T2-T6).In our study, addition of dexmedetomidine has 
significantly increased the highest level of sensory blockade attained much 
more than even clonidine. Since dexmedetomidine has a higher sensory 
level of blockade (T2-T6) the possibility of dexmedetomidine used for supra 
umbilical abdominal surgeries  should be explored.  
 Kanazi et a
40
 in his study found that addition of intrathecal Clonidine 
30 µgms and Dexmedetomidine 3 µgms to 0.75% Bupivacaine resulted in a 
much lower peak sensory levels in comparision to our study.(Group B 
T6(T4-10),group C T6.5(T3-9),group D T6(T 10)). This could be due to 
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lower dosage of Clonidine and Dexmedetomidine  and lower volume of the 
drug administered used by Kanazi et al.
40
 
MAXIMUM MOTOR BLOCK ATTAINED: 
The median of maximum grade of motor block attained was grade 3 
in all the groups measured using modified bromage scale. There is no 
statistically significant difference among the groups. 
Klimscha et a123 showed that intrathecal clonidine 150 µgms added to 
0.5% bupivacaine significantly increased the intensity of motor block. 
Bonnet et al3 in his study found that intensity and duration of motor 
block was prolonged with increasing the dose of clonidine from 75 mics to 
150 mics added to 0.5% tetracaine 15mg. 
TIME FOR TWO SEGMENTAL REGRESSION: 
The mean time taken for two segmental regression was 99.53mins in 
group C compared to 136.55 mins in group D. Group D had significantly 
prolonged two segmental regression time compared to C&B(77mins).  
This correlated well with the studies of  Al-Mustafa et al
41,43 
 and 
Kanazi et al.
40 
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MEAN DURATION OF MOTOR BLOCK: 
The mean duration of motor block was 148.5mins in group B, 
compared to 205.9mins in group C & 262mins in Group D. Both ANOVA 
and Post Hoc test showed significant difference between the groups. 
Dexmedetomidine has a prolonged motor blockade, hence  a longer post 
operative care unit admission and hence preventing an earlier discharge. 
Kanazi et al
40
 shows similar results(163, 216,250mins) respectively, 
Al Musthafa et al
41,43 
 demonstrated (140,246mins) in group B and D5 
respectively. Which correlates with our study if we take the dosage and 
volume of the drugs in to consideration. 
MEAN DURATION OF SENSORY BLOCKADE 
The mean duration of  sensory regression to first sacral dermatome 
was 179.8 mins in group B compared to 265.5 mins in group C & 338min 
Group D, which were statisticaly significant both by ANOVA and 
Bonferroni’s Post Hoc analysis. Hence is produces  prolonged periods of 
pain relief  which correlates well with duration of analgesia. This correlated 
with study by kanazi et al
40
where there was significant prolongation of 
sensory blockade (190, 272, 303 mins in Group B,C,D respectively) 
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Dobrydnjov et al 
11
 also showed in his study that clonidine added to 
small dose bupivacaine for inguinal hernioraphy had prolonged analgesia 
compared to control group. 
Gautier et al 
20
 showed in his study that clonidine combined with 
sufentanil for first stage of labour significantly prolonged analgesia 
compared with sufentanil alone. 
Study by Mercier et a1 
27
 showed addition of clonidine to intrathecal 
sufentanil for labour significantly prolonged analgesia. 
Hemodynamic Characteristics 
Both Clonidine and dexmeditomidine lowered the pulse rate,systolic 
BP, diastolic BP. But in clonidine lowering of Systolic BP was significant 
and sustained for a prolonged period. Hence higher dosages of clonidine 
should be used with caution in SAB. Hypotension was observed in 5-10% of 
patients in clonidine group. Hypotension was treated with ephedrine and 
bradycardia with Atropine. 
Study by Chiari Astrid et a1
7
 on analgesic and hemodynamic effects 
of  intrathecal clonidine as a sole analgesic agent during first stage of labour 
showed hypotension was produced by increasing doses of clonidine. 
 
75
Study by Fibs kriton et a1
14
 found that hypotension is the main side 
effect. 
Studies done by Freedman JM et a11
7
 and J4ampl KF et a1
22
 showed 
an increased occurrence of TNS in patients undergoing spinal anaesthesia 
with lignocaine. 
Sedation 
In our study patients in clonidine groups had deeper levels of sedation 
with RSS score 3.3 , which did not require any active intervention. 
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CONCLUSION 
In conclusion the addition of Clonidine and Dexmedetomidine as 
adjuvants to bupivacaine in subarachnoid block, shortens the onset and 
prolongs the duration of both sensory and motor block. 
We conclude that 5µgm of dexmedetomidine added to local 
anaesthetic in comparison to 50µgm of clonidine in subarachnoid block is 
more potent with respect to both onset and duration of sensory and motor 
blockade. Even though dexmedetomidine produced a lowering of heart rate 
and blood pressure they were not severe enough to warrant active 
intervention in most of the cases but the same cannot be said about higher 
dosages of clonidine. 
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1 C MADHAVAN 36 m   60 164 120 2 90 270 210 305 26 6 3 3 6 
2 C VENKATESAN 50 m 62 160 100 2 90 260 200 325 28 5 3.5 3 6 
3 C MOHANAVEL 46 m 54 156 65 2 75 240 190 325 30 4 3 3 4 
4 C ANJALATCHI 50 f 50 145 60 2 120 270 210 340 34 4 3 4 4 
5 C RAJA 36 m    56 158 120 3 100 265 200 320 20 5 3.5 4 4 
6 C SUNDER 40 M 68 156 60 3 110 250 205 310 28 4 4 5 4 
7 C LUND MARY 36 f 44 163 50 3 125 265 210 325 29 4 3 5 4 
8 C AGASAN 45 m 53 165 75 3 110 250 180 290 30 4 3 4 4 
9 C PADMANATHAN 45 m 62 142 70 2 120 270 200 325 24 6 6 4 6 
10 C VELU 40 m 55 166 150 4 125 250 210 285 25 6 5 2 6 
11 C ARAVIND 26 m 49 150 100 2 115 250 185 290 26 4 5 5 4 
12 C MANI 45 m 70 152 190 2 90 250 190 310 28 4 5 6 4 
13 C RAJESH 36 m 45 157 150 2 80 280 235 310 20 6 6 5 6 
14 C SUBRAMANI 46 m 57 174 90 2 85 285 220 295 24 6 4 4 6 
15 C RAVISHANKAR 26 m 54 154 75 2 85 280 210 310 23 6 4 4 6 
16 C NEELANKANDAN 21 m 45 158 100 3 110 270 220 310 28 4 6 3 4 
17 C RAMESH 24 m 50 169 90 3 125 250 215 300 28 6 4 3 6 
18 C GUNALAN 38 M 64 149 45 2 100 280 230 305 32 4 4 4 4 
19 C RAVI 39 m 44 154 135 2 120 260 190 305 28 5 5 3 6 
20 C AYYASWAMY 45 m 60 142 105 2 75 270 190 300 35 3 3 5 6 
6 C SELVARANI           30 f 55 164 120 2 100 275 215 305 21 5 2 2 
7 C RAMAYEE             48 f 41 158 140 3 100 280 220 310 30 3 2 3 
10 C FATHIMA             31 f 55 150 90 4 110 285 225 290 30 4 4 5 
11 C KAKKAPPAN           51 m 52 164 100 3 110 280 220 325 15 6 5 4 
21 C GANESAN             33 m 45 158 75 3 95 290 230 320 15 6 3 3 
29 C GOVINDAMMAL         42 f 60 156 80 2 85 260 210 280 30 5 5 3 
30 C MURUGESHWARAN 18 m 50 155 110 2 70 250 190 280 35 5 5 3 
31 C GANESAN             51 m 56 158 120 2 100 245 180 265 27 6 3 4 
33 C JEYAKUMAR           27 m 50 158 135 2 100 245 180 275 25 4 5 6 
34 C MEGALA              18 f 45 150 115 3 80 280 200 320 26 6 5 5 
35 C NIRMAL KUMAR        26 m 54 172 105 3 75 270 210 310 22 6 3 3 
39 C SELVAM              45 m 65 160 85 2 85 270 210 320 26 6 4 4 
1 B PARTHASARATHY 50 m 56 170 70 1 85 150 125 100 15 6 6 6 
2 B VENU 28 m 45 164 100 1 80 180 150 130 19 7 7 7 
3 B PARTAHASARATHY 50 m 60 172 45 1 70 190 160 120 22 6 7 7 
4 B MALA 36 f 58 156 100 2 75 145 110 90 24 5 5 7 
5 B PERUMAL 42 m 45 164 45 1 75 155 115 100 18 8 6 7 
6 B RAMANI 36 f 56 161 120 2 80 200 170 130 14 9 7 9 
7 B MAGALA 46 f 50 148 120 1 85 180 160 120 15 8 8 9 
8 B SARATH 37 m 70 160 70 2 75 190 165 120 20 5 8 7 
9 B VIJATSARATHI 20 m 40 158 60 2 70 200 165 120 23 6 5 5 
10 B MADHAVAN 29 m 45 164 120 1 70 170 155 110 17 7 7 9 
11 B RAJA 35 m 68 161 80 2 85 170 140 115 22 6 5 5 
12 B MURUGAN 25 m 50 163 135 2 85 190 150 120 14 9 7 6 
13 B NITHYANANDAM 22 m 58 156 120 2 80 180 145 110 16 8 6 5 
14 B CHELLAMUTHU 50 m 70 154 105 2 80 180 135 100 18 7 5 6 
15 B GUNASEKARAN 38 m 49 156 70 2 65 185 150 120 18 6 6 8 
16 B KOKILA 45 m 69 166 80 1 70 180 155 100 22 6 6 6 
17 B LOGONATHAN 38 m 54 165 90 2 70 185 150 125 19 7 7 9 
18 B DEVBARARATH 22 m 49 162 130 2 75 200 145 145 16 9 6 7 
19 B INIYAN 40 m 64 164 70 2 75 200 165 135 24 7 6 6 
20 B MADHIVANI 36 f 50 168 130 2 80 165 125 110 18 10 5 7 
 B SURESH 35 M 44 158 60 1 65 185 150 120 18 6 6 8 
 B CHANDRAN 57 M 60 180 75 2 70 180 155 100 22 6 6 6 
     B SENTHIL 39 m 60 160 70 2 75 160 135 110 18 8 6 7 
 B PUGAZHENDHI 35 m 55 162 90 2 85 170 145 115 24 7 9 9 
 B GOODFRED 41 m 60 155 85 2 80 175 145 120 22 6 6 6 
 B SANTHOSAM 44 m 52 160 70 1 70 175 145 150 20 8 7 7 
 B ESWARI 54 F 50 150 100 2 100 190 165 125 18 6 6 7 
 B KUPPAN 32 m 60 165 120 2 80 190 165 120 22 5 6 6 
 B GAYATHRI 56 F 55 160 110 2 80 150 110 90 24 6 5 6 
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 B SUDHA 27 f 65 170 100 2 75 190 160 95 15 7 7 8 
 B KARI 53 m 65 160 90 1 75 200 175 120 18 9 5 8 
 B PITCHAIAH 28 m 55 155 75 1 100 195 165 120 22 8 8 9 
 B POTHUMPONNU 46 f 50 150 75 2 65 185 160 110 24 8 7 7 
40 D VAIKUNDAM           40 m 54 165 150 2 145 310 240 340 15  2 3 5 
32 D SULOCHANA 43 f 62 164 70 2 140 360 280 380 23 3 3 3 4 
36 D ANANDHA KUMAR       18 m 47 163 100 3 135 400 310 410 23 2 3 4 3 
1 D MURUGAN             55 m 55 160 65 2 130 366 290 325 35 4 4 3 3 
2 D KANDHAN 60 m 67 158 75 2 140 275 220 330 15 5 2 3 2 
3 D PERIYASAMY          55 m 60 162 80 2 145 280 230 335 40 2 3 3 4 
4 D VELLAISAMY          42 m 70 168 145 2 135 330 270 380 12 6 3 2 5 
5 D PACHAI KANI         67 f 46 146 75 2 130 345 265 375 15 6 3 3 2 
8 D MARI                34 m 37 164 105 3 130 355 270 375 16 5 2 3 5 
9 D PALANI 68 m 53 168 120 2 145 380 280 380 15 2 2 3 2 
12 D VEERANNAN           52 m 46 160 140 2 145 335 250 365 21 3 3 3 4 
13 D DHARMARAJ           38 m 40 148 70 2 140 365 270 370 21 4 6 3 3 
14 D SUBRAMANI           43 m 58 170 90 2 140 345 260 380 24 4 3 3 5 
15 D ALAZHAR             60 m 39 156 105 2 155 360 270 390 21 3 3 3 5 
16 D MURUGAN 38 m 58 178 90 2 150 370 290 385 15 5 3 3 4 
17 D KALA 35 f 54 172 40 2 125 370 285 390 21 5 5 3 3 
18 D VANI 64 F 73 160 50 2 130 320 270 355 16 4 3 4 5 
19 D KARUPPAN            56 m 60 168 120 3 130 310 260 345 21 3 3 3 4 
20 D GNANAPANDITHAN      27 m 54 152 60 2 130 310 260 350 21 5 3 5 4 
22 D CHANDRASEKAR 45 m 60 156 90 2 110 280 230 340 16 4 6 5 5 
23 D SRINIVASAN          43 m 65 166 65 2 140 275 220 330 16 4 4 4 4 
24 D KASI VISHWANATHAN   54 m 66 162 60 2 125 290 250 345 24 4 5 3 2 
25 D SOUNDARAJAN         54 m 85 160 90 2 145 335 250 370 19 4 3 3 3 
26 D DULEEP              24 m 48 158 90 3 150 335 260 360 16 4 5 3 6 
27 D JEYAKUMAR           29 m 50 160 115 2 110 340 260 375 25 2 4 4 4 
28 D PETCHI AMMA 38 F 57 166 90 2 160 355 270 385 22 3 3 3 5 
37 D SARAVANAN           24 m 48 160 75 2 140 355 265 370 60 6 3 4 2 
38 D KARUPPIAH           40 m 55 165 120 3 140 360 265 380 15 4 2 3 4 
43 D CHINNAKALAI 65 m 50 162 120 2 120 390 270 400 30 5 3 3 5 
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96 98 102 108 110 100 96 100 96 100 101 96 94 92 80 94 90 101 100 110 113 110
70 64 65 60 66 64 68 70 65 68 66 64 66 65 66 64 62 64 62 60 64 64
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86 82 80 76 72 76 76 76 76 72 72 72 68 72 84 88 88 88 72 73 73 73
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